11 - 14 out of 14Page size: 10
Sort by: Title

  1. NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.

    Alsalloum, A., Shevchenko, J. A. & Sennikov, S., Sept 2024, In: Clinical and translational medicine. 14, 9, p. e70020

    Research output: Contribution to journal › Review article › peer-review

  2. Hyaluronic Acid-Based Drug Delivery Systems for Cancer Therapy

    Pashkina, E., Bykova, M., Berishvili, M., Lazarev, Y. & Kozlov, V., 7 Jan 2025, In: Cells. 14, 2, 61.

    Research output: Contribution to journal › Article › peer-review

  3. Decoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model

    Alsalloum, A., Alrhmoun, S., Perik-Zavosdkaia, O., Fisher, M., Volynets, M., Lopatnikova, J., Perik-Zavodskii, R., Shevchenko, J., Philippova, J., Solovieva, O., Zavjalov, E., Kurilin, V., Shiku, H., Silkov, A. & Sennikov, S., 2024, In: Frontiers in Immunology. 15, 11 p., 1507218.

    Research output: Contribution to journal › Article › peer-review

  4. Acute blood loss in mice forces differentiation of both CD45-positive and CD45-negative erythroid cells and leads to a decreased CCL3 chemokine production by bone marrow erythroid cells

    Nazarov, K., Perik-Zavodskii, R., Perik-Zavodskaia, O., Alrhmoun, S., Volynets, M., Shevchenko, J. & Sennikov, S., Sept 2024, In: PLoS ONE. 19, 9, 18 p., e0309455.

    Research output: Contribution to journal › Article › peer-review

Previous 1 2 Next

ID: 59990271